Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Nov 26, 2025, 4:00 PM EST
1.340
+0.020 (1.52%)
After-hours: Nov 26, 2025, 7:15 PM EST
Cibus Revenue
Cibus had revenue of $615.00K in the quarter ending September 30, 2025, a decrease of -63.11%. This brings the company's revenue in the last twelve months to $3.79M, down -8.64% year-over-year. In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth.
Revenue (ttm)
$3.79M
Revenue Growth
-8.64%
P/S Ratio
13.60
Revenue / Employee
$23,862
Employees
159
Market Cap
71.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
| Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
| Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
| Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
| Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CBUS News
- 13 days ago - Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025 - GlobeNewsWire
- 15 days ago - Cibus Announces the Election of Craig Wichner to Board of Directors - GlobeNewsWire
- 27 days ago - Cibus to Report Third Quarter 2025 Financial Results on November 13, 2025 After the Market Close and Host Conference Call - GlobeNewsWire
- 5 weeks ago - Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing - GlobeNewsWire
- 6 weeks ago - Soybean Short Squeeze: Cooking Oil Stocks Pop After Trump Targets China - Benzinga
- 7 weeks ago - Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola - GlobeNewsWire
- 2 months ago - Cibus Announces the Election of Kimberly A. Box to Board of Directors - GlobeNewsWire